AU · rank #1 · 2026-07-23
DIA
GPW · PLN · $1.51B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.518 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.38 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $204.28 | +20.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +15.41% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.33 |
| Gross margin TTM | +79.3% |
| 52w high | $214.46 |
| Market cap (USD) | $1.51B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Diagnostyka S.A. operates Poland's leading nationwide medical diagnostics network, delivering over 4,000 laboratory and imaging tests through more than 150 laboratories and 1,100 blood collection points.
Rationale
The 20.6% analyst upside is backed by strong Q1 2026 results featuring mid-teens revenue and net profit growth, a 79.3% gross margin, and return on equity above 40%.
Material risks
- 1Long-term technological shift toward point-of-care and home diagnostics could commoditize routine tests and displace the company's centralized laboratory model.
- 2Key institutional customers, such as medical facilities and universities, could insource diagnostic capabilities or cancel major contracts, reducing volume.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.